All patients
critical disease severe disease
sarilumab low dose (200mg) in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12]
sarimulab phase 2 low dose, 0 1.51 [0.69; 3.32]
1.39 [0.76 ; 2.53 ] Lescure (Sarilumab 200mg), 2021, sarimulab phase 2 low dose, 0 2 0% 381 serious not evaluable clinical improvementdetailed results Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
sarimulab phase 2 low dose, 0 1.51 [0.73; 3.11]
1.09 [0.82 ; 1.46 ] Lescure (Sarilumab 200mg), 2021, sarimulab phase 2 low dose, 0 2 0% 385 moderate not evaluable clinical improvement (time to event analysis only)detailed results Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
sarimulab phase 2 low dose, 0 0.96 [0.53; 1.73]
1.01 [0.77 ; 1.34 ] Lescure (Sarilumab 200mg), 2021, sarimulab phase 2 low dose, 0 2 0% 494 moderate not evaluable death or ventilationdetailed results sarimulab phase 2 low dose, 0 0.70 [0.34; 1.44]
0.70 [0.34 ; 1.44 ] sarimulab phase 2 low dose, 0 1 0% 138 NA not evaluable mechanical ventilationdetailed results sarimulab phase 2 low dose, 0 0.28 [0.11; 0.73]
0.28 [0.11 ; 0.73 ] sarimulab phase 2 low dose, 0 1 0% 138 NA not evaluable off oxygenationdetailed results sarimulab phase 2 low dose, 0 1.07 [0.52; 2.21]
1.07 [0.52 ; 2.21 ] sarimulab phase 2 low dose, 0 1 0% 138 NA not evaluable serious adverse eventsdetailed results Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12]
1.15 [0.62 ; 2.12 ] Lescure (Sarilumab 200mg), 2021 1 0% 243 NA not evaluable adverse eventsdetailed results Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69]
0.97 [0.56 ; 1.69 ] Lescure (Sarilumab 200mg), 2021 1 0% 243 NA not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-27 14:00 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 645
- roots T: 290
